The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia

2.50
Hdl Handle:
http://hdl.handle.net/2336/75697
Title:
The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia
Authors:
Bang, Peter; Laursen, Inga; Thornberg, Klaus; Schierbeck, Jens; Nielsen, Bjarne; Valdimarsson, Helgi; Koch, Claus; Christiansen, Michael
Citation:
Scand. J. Infect. Dis. 2008, 40(1):44-8
Issue Date:
2008
Abstract:
Mannan-binding lectin (MBL) is a member of the innate immune system, and MBL-deficiency affects 10-15% of Caucasians. With development of a plasma-derived MBL, substitution has become a therapeutic option in diseases associated with MBL insufficiency. The pharmacokinetics of injected MBL is weakly described, particularly in patients with infectious diseases. The pharmacokinetic profile of MBL following administration of 0.08 mg/kg to 20 healthy MBL-deficient volunteers and 0.2 mg/kg to 2 patients with Staphylococcus aureus septicaemia was established. In the volunteers, the maximal concentration was 2849 microg/l; the mean half-life (T(1/2)) was 69.6 h (14.6-114.9 h). The normalized clearance was 9x10(-6) l/minxkg, and the mean residence time was 82 h. In the patients the serum-MBL versus time curves were similar to those in the volunteers, and T(1/2) values were 36 and 40 h. In conclusion, MBL is distributed into a median volume of 3.4 l similar to the plasma volume, and the elimination in septicaemic patients was within the range of the controls. Due to the large individual variation in T(1/2), we recommend that MBL therapy, with respect to dose and infusion intervals, is based on the chosen therapeutic target (> or =1000 microg/l) and MBL serum determinations following the first infusion.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1080/00365540701522959

Full metadata record

DC FieldValue Language
dc.contributor.authorBang, Peter-
dc.contributor.authorLaursen, Inga-
dc.contributor.authorThornberg, Klaus-
dc.contributor.authorSchierbeck, Jens-
dc.contributor.authorNielsen, Bjarne-
dc.contributor.authorValdimarsson, Helgi-
dc.contributor.authorKoch, Claus-
dc.contributor.authorChristiansen, Michael-
dc.date.accessioned2009-07-27T11:52:36Z-
dc.date.available2009-07-27T11:52:36Z-
dc.date.issued2008-
dc.date.submitted2009-07-27-
dc.identifier.citationScand. J. Infect. Dis. 2008, 40(1):44-8en
dc.identifier.issn0036-5548-
dc.identifier.pmid17852940-
dc.identifier.doi10.1080/00365540701522959-
dc.identifier.urihttp://hdl.handle.net/2336/75697-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractMannan-binding lectin (MBL) is a member of the innate immune system, and MBL-deficiency affects 10-15% of Caucasians. With development of a plasma-derived MBL, substitution has become a therapeutic option in diseases associated with MBL insufficiency. The pharmacokinetics of injected MBL is weakly described, particularly in patients with infectious diseases. The pharmacokinetic profile of MBL following administration of 0.08 mg/kg to 20 healthy MBL-deficient volunteers and 0.2 mg/kg to 2 patients with Staphylococcus aureus septicaemia was established. In the volunteers, the maximal concentration was 2849 microg/l; the mean half-life (T(1/2)) was 69.6 h (14.6-114.9 h). The normalized clearance was 9x10(-6) l/minxkg, and the mean residence time was 82 h. In the patients the serum-MBL versus time curves were similar to those in the volunteers, and T(1/2) values were 36 and 40 h. In conclusion, MBL is distributed into a median volume of 3.4 l similar to the plasma volume, and the elimination in septicaemic patients was within the range of the controls. Due to the large individual variation in T(1/2), we recommend that MBL therapy, with respect to dose and infusion intervals, is based on the chosen therapeutic target (> or =1000 microg/l) and MBL serum determinations following the first infusion.en
dc.language.isoenen
dc.publisherInforma Healthcareen
dc.relation.urlhttp://dx.doi.org/10.1080/00365540701522959en
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshCase-Control Studiesen
dc.subject.meshDose-Response Relationship, Drugen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunologic Factorsen
dc.subject.meshInfusions, Intravenousen
dc.subject.meshMaleen
dc.subject.meshMannose-Binding Lectinen
dc.subject.meshMiddle Ageden
dc.subject.meshSepsisen
dc.subject.meshStaphylococcal Infectionsen
dc.titleThe pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemiaen
dc.typeArticleen
dc.contributor.departmentDepartment of Vaccine Development, Statens Serum Institut, Copenhagen, Denmark.en
dc.identifier.journalScandinavian journal of infectious diseasesen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.